We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series / Moccia, Marcello; Buonomo, Antonio Riccardo; Scotto, Riccardo; Viceconte, Giulio; Nobile, Mariano; Lanzillo, Roberta; Brescia Morra, Vincenzo; Gentile, Ivan. - In: JOURNAL OF THE NEUROLOGICAL SCIENCES. - ISSN 0022-510X. - 439:(2022), p. 120306. [10.1016/j.jns.2022.120306]
Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
Moccia, Marcello;Buonomo, Antonio Riccardo;Scotto, Riccardo;Viceconte, Giulio;Nobile, Mariano;Lanzillo, Roberta;Brescia Morra, Vincenzo;Gentile, Ivan
2022
Abstract
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.